Monday, the genetic pharmaceutical company Regeneron announced that it is buying genetic sequencing company 23andMe out of bankruptcy for $256 million. The purchase gives us a rough estimate for the current monetary value of a single person’s genetic data: $17.

Regeneron is a drug company that “intends to acquire 23andMe’s Personal Genome Service (PGS), Total Health and Research Services business lines, together with its Biobank and associated assets, for $256 million and for 23andMe to continue all consumer genome services uninterrupted,” the company said in a press release Monday. Regeneron is working on personalized medicine and new drug discovery, and the company itself has “sequenced the genetic information of nearly three million people in research studies,” it said. This means that Regeneron itself has the ability to perform DNA sequencing, and suggests that the critical thing that it is acquiring is 23andMe’s vast trove of genetic data.